ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Respiratory, thoracic, and mediastinal adverse events associated with ticagrelor: A pharmacovigilance study based on FDA adverse event reporting system.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ticagrelor has been authorized for use as an antiplatelet therapy in individuals diagnosed with acute coronary syndrome (ACS). While numerous clinical trials have reported respiratory-related AEs associated with ticagrelor, real-world evidence from large populations remains limited. In this study, we aimed to assess the safety signals of respiratory, thoracic, and mediastinal disorders related to ticagrelor using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).This study utilized data from the FAERS database spanning 2011 to 2024. The reporting odds ratio (ROR) was used to quantify safety signals of respiratory, thoracic, and mediastinal adverse events associated with ticagrelor. Chi-square (χ
Indexed as
Identifiers
40668413What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.